The stock of Cellectar Biosciences Inc (NASDAQ:CLRB) is a huge mover today! About 169,952 shares traded hands. Cellectar Biosciences Inc (NASDAQ:CLRB) has declined 44.90% since March 2, 2016 and is downtrending. It has underperformed by 53.16% the S&P500.
The move comes after 6 months negative chart setup for the $13.91 million company. It was reported on Oct, 5 by Barchart.com. We have $2.25 PT which if reached, will make NASDAQ:CLRB worth $1.95 million less.
Analysts await Cellectar Biosciences Inc (NASDAQ:CLRB) to report earnings on November, 10. They expect $-0.20 EPS, up 92.00% or $2.30 from last year’s $-2.5 per share. After $-0.49 actual EPS reported by Cellectar Biosciences Inc for the previous quarter, Wall Street now forecasts -59.18% EPS growth.
According to Zacks Investment Research, “Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.”
More notable recent Cellectar Biosciences Inc (NASDAQ:CLRB) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on February 24, 2014, also Streetinsider.com with their article: “Cellectar Biosciences (CLRB) Receives U.S. Patent Related to CLR 1603” published on October 04, 2016, Seekingalpha.com published: “Cellectar Biosciences: Hype Versus Science” on May 23, 2016. More interesting news about Cellectar Biosciences Inc (NASDAQ:CLRB) were released by: Jsonline.com and their article: “Cellectar Biosciences raises $8 million in secondary offering” published on April 20, 2016 as well as Streetinsider.com‘s news article titled: “Cellectar Biosciences (CLRB) Announces Positive Data from Second Cohort of CLR …” with publication date: September 29, 2016.
CLRB Company Profile
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., incorporated on June 24, 1996, is a clinical stage biopharmaceutical company. The Firm is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer targeting delivery platform. The Company’s platform helps in discovery and development of a range of cancer targeting agents. The Company’s pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, CLR 125, CLR 124, CLR 1502 and CTX Product Portfolio.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.